What question did this study set out to answer?

To determine whether alleviating endoplasmic reticulum stress and modulating the unfolded protein response with IFB-088 can treat neuropathy in CMT1A and CMT1B mouse models.

April 30, 2022Molecular NeurobiologyOpen Access

Treatment with IFB-088 Improves Neuropathy in CMT1A and CMT1B Mice

View Full Paper

Ask AI

Bookmark

Authors

YBYunhong BaiShaanxi University of Science and Technology CTCaroline TreinsCentre National de la Recherche Scientifique VVVera G. VolpiVita-Salute San Raffaele University

Discussion

Member takes

Overview

Preclinical study demonstrates motor and neurophysiological improvements in CMT1A and CMT1B mice treated with IFB-088, indicating its therapeutic potential for demyelinating neuropathies.

Key Points

To determine whether alleviating endoplasmic reticulum stress and modulating the unfolded protein response with IFB-088 can treat neuropathy in CMT1A and CMT1B mouse models.
Administered the unfolded protein response modulator Sephin1/IFB-088/icerguestat to heterozygous MpzR98C/+ and C3-PMP22 mice.
Assessed therapeutic outcomes via behavioral, neurophysiological, morphological (including g-ratios and myelin thickness), and biochemical evaluations.
IFB-088 treatment resulted in improved motor function and neurophysiological performance in both MpzR98C/+ and C3-PMP22 mice.
Myelination parameters, such as g-ratios and myelin thickness, improved alongside the restoration of unfolded protein response activation markers toward wild-type levels.

Cite This Study

Bai et al. (2022) studied this question.

synapsesocial.com/papers/6a926d170e9b60bc4641f5a2 https://doi.org/10.1007/s12035-022-02838-y

View Full Paper

Ask AI

Bookmark

April 30, 2022Molecular NeurobiologyOpen Access

Treatment with IFB-088 Improves Neuropathy in CMT1A and CMT1B Mice

View Full Paper

Ask AI

Bookmark

Authors

YBYunhong BaiShaanxi University of Science and Technology CTCaroline TreinsCentre National de la Recherche Scientifique VVVera G. VolpiVita-Salute San Raffaele University

Discussion

Member takes

Overview

Preclinical study demonstrates motor and neurophysiological improvements in CMT1A and CMT1B mice treated with IFB-088, indicating its therapeutic potential for demyelinating neuropathies.

Key Points

To determine whether alleviating endoplasmic reticulum stress and modulating the unfolded protein response with IFB-088 can treat neuropathy in CMT1A and CMT1B mouse models.
Administered the unfolded protein response modulator Sephin1/IFB-088/icerguestat to heterozygous MpzR98C/+ and C3-PMP22 mice.
Assessed therapeutic outcomes via behavioral, neurophysiological, morphological (including g-ratios and myelin thickness), and biochemical evaluations.
IFB-088 treatment resulted in improved motor function and neurophysiological performance in both MpzR98C/+ and C3-PMP22 mice.
Myelination parameters, such as g-ratios and myelin thickness, improved alongside the restoration of unfolded protein response activation markers toward wild-type levels.

Cite This Study

Bai et al. (2022) studied this question.

synapsesocial.com/papers/6a926d170e9b60bc4641f5a2 https://doi.org/10.1007/s12035-022-02838-y

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark